# ANSWER (NCT04455594)

> Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

No report yet. It can be ordered.

- Indication: stage IIIA-N2 EGFR-mutated NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04455594
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: The First Affiliated Hospital of Guangzhou Medical University
- Conditions: Non-Small Cell Lung Cancer Stage IIIA
- Interventions: Almonertinib; Erlotinib; Cisplatin; Carboplatin; Pemetrexed
- Enrollment: 168
- Primary outcome: Objective response rate (ORR)

## Indexed commentary on ANSWER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=answer-nct04455594